162 related articles for article (PubMed ID: 34195239)
21. A multicenter post-marketing evaluation of the Elixir DESolve
Nef H; Wiebe J; Boeder N; Dörr O; Bauer T; Hauptmann KE; Latib A; Colombo A; Fischer D; Rudolph T; Foin N; Richardt G; Hamm C
Catheter Cardiovasc Interv; 2018 Nov; 92(6):1021-1027. PubMed ID: 29508518
[TBL] [Abstract][Full Text] [Related]
22. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
[TBL] [Abstract][Full Text] [Related]
23. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
[TBL] [Abstract][Full Text] [Related]
24. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
[TBL] [Abstract][Full Text] [Related]
25. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
26. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
[TBL] [Abstract][Full Text] [Related]
27. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.
Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R
Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817
[TBL] [Abstract][Full Text] [Related]
28. Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds.
Gunes HM; Gokdeniz T; Kizilirmak Yilmaz F; Demir GG; Guler E; Babur Guler G; Karaca O; Cakal B; Omaygenç MO; İbişoğlu E; Boztosun B
J Interv Cardiol; 2017 Jun; 30(3):189-194. PubMed ID: 28440067
[TBL] [Abstract][Full Text] [Related]
29. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.
Nef HM; Wiebe J; Schmidt G; Möllmann H; Boeder NF; Dörr O; Bauer T; Blachutzik F; Liebetrau C; Elsässer A; Foin N; Hamm CW
Herz; 2020 Dec; 45(Suppl 1):95-104. PubMed ID: 31209520
[TBL] [Abstract][Full Text] [Related]
30. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
[TBL] [Abstract][Full Text] [Related]
31. The DESolve novolimus bioresorbable Scaffold: from bench to bedside.
Mattesini A; Bartolini S; Sorini Dini C; Valente S; Parodi G; Stolcova M; Meucci F; Di Mario C
J Thorac Dis; 2017 Aug; 9(Suppl 9):S950-S958. PubMed ID: 28894601
[TBL] [Abstract][Full Text] [Related]
32. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome.
Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332
[TBL] [Abstract][Full Text] [Related]
33. Two-year longitudinal evaluation of a second-generation thin-strut sirolimus-eluting bioresorbable coronary scaffold with hybrid cell design in porcine coronary arteries.
Gasior P; Cheng Y; Xia J; Conditt GB; McGregor JC; Virmani R; Granada JF; Kaluza GL
Cardiol J; 2020; 27(2):115-125. PubMed ID: 30155861
[TBL] [Abstract][Full Text] [Related]
34. In vitro mechanical behavior and in vivo healing response of a novel thin-strut ultrahigh molecular weight poly-l-lactic acid sirolimus-eluting bioresorbable coronary scaffold in normal swine.
Cheng Y; Gasior P; Ramzipoor K; Lee C; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
Int J Cardiol; 2019 Jul; 286():21-28. PubMed ID: 30967275
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.
Rola P; Włodarczak A; Łanocha M; Barycki M; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Gosiewska A; Woźnica K; Lesiak M; Doroszko A
Cardiol J; 2022 May; 30(6):870-80. PubMed ID: 35621089
[TBL] [Abstract][Full Text] [Related]
36. Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.
Włodarczak A; Rola P; Szudrowicz M; Łanocha M; Barycki M; Kulczycki JJ; Gosiewska A; Turkiewicz K; Lesiak M; Doroszko A
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501216
[TBL] [Abstract][Full Text] [Related]
37. Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
Cheng Y; Gasior P; Xia JG; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
Circ Cardiovasc Interv; 2017 Jul; 10(7):. PubMed ID: 28701488
[TBL] [Abstract][Full Text] [Related]
38. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition).
Ormiston JA; Webber B; Ubod B; Darremont O; Webster MW
EuroIntervention; 2015 May; 11(1):60-7. PubMed ID: 25680225
[TBL] [Abstract][Full Text] [Related]
39. Optimal lesion preparation before implantation of a Magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the OPTIMIS study.
Hansen KN; Maehara A; Noori M; Trøan J; Fallesen CO; Hougaard M; Ellert-Gregersen J; Veien KT; Junker A; Hansen HS; Lassen JF; Jensen LO
Contemp Clin Trials Commun; 2024 Apr; 38():101260. PubMed ID: 38384894
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients' Population.
Al Nooryani A; Aboushokka W; AlBaba B; Kerfes J; Abudaqa L; Bhatia A; Mansoor A; Nageeb R; Aleksandric S; Beleslin B
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807011
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
